Last reviewed · How we verify
Betamican
Betamican is a Small molecule drug developed by Fundacio Privada Mon Clinic Barcelona. It is currently FDA-approved. Also known as: LABA.
Betamican, marketed by Fundacio Privada Mon Clinic Barcelona, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Betamican |
|---|---|
| Also known as | LABA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betamican CI brief — competitive landscape report
- Betamican updates RSS · CI watch RSS
- Fundacio Privada Mon Clinic Barcelona portfolio CI
Frequently asked questions about Betamican
What is Betamican?
Who makes Betamican?
Is Betamican also known as anything else?
What development phase is Betamican in?
Related
- Manufacturer: Fundacio Privada Mon Clinic Barcelona — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: LABA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing